Search

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

Leticia develops product medical strategies

Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.

Laura loves her diverse career

Laura loves her diverse career at Boehringer Ingelheim. For more talent insights, visit our Careers Page.

Learning and development

We help people grow professionally by maximizing our talent and giving them room to evolve within the company.

Global mobility

We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.

Dirk Stenkamp

Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.

Lothar Halmer

Dr. Lothar Halmer is our Chief Quality Officer, and proud to have built a 25-year career with us.

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases

New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health

Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.

Simon Manyara

Simon Manhara works with our culture and sustainability team towards making a positive social impact and creating a sustainable future.

Galym Zhunisbekov

Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.

Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US

Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.

Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US

Read more on Boehringer Ingelheim Vetmedica Inc. entering into an agreement to sell feline, canine and rabies vaccines to Elanco Animal Health in the USA.

Exploring beyond boundaries for innovation in animal health

Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

FDA accepts Jardiance sNDA for T2D in children 10 and older

The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers